Maykin Ho

October 13, 2026

AGIO Valuation Concerns Ahead of Q3 2026 Call. AGIO’s November earnings call sparked debate that the shares might be undervalued by about 28%, while analysts noted the stock appears fully priced against current sales. The company will host its third‑quarter 2026 results call on Nov. 5, which could clarify expectations. After a 29% decline over three months, Truist Securities lowered its target price to $37, reflecting a more cautious view.

October 4, 2026

BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.

October 15, 2026

NMRA noted among top stock movers today. NMRA appeared in today's list of top stock movements, reflecting notable price activity. The stock is currently trading near its support level of $1.60 and shows a low RSI, suggesting oversold conditions. Analyst consensus target remains at $6.14, well above the current price range.

October 2, 2026

Kyntra Bio Names Andrew Singer to Board. Kyntra Bio has added Andrew E. Singer, MBA, to its board of directors. The move expands the company’s leadership team and could bring new expertise to its strategic planning. The appointment follows the company’s ongoing efforts to strengthen governance and support its growth initiatives. Investors may view the change as a sign of continued focus on development and operational improvement.